Table 1.
Validity of breast cancer flags in individual datasets compared with the Cancer Registry, July 2004-December 2008
| Data set | Breast cancer flags | Positive predictive value | Sensitivity | Specificity |
|---|---|---|---|---|
| 45 and Up baseline survey1 |
Self-reported diagnosis of breast cancer 2 within a year of birth-year reported |
49.8% |
84.7% |
99.6% |
| Admitted Patient Data Collection |
Diagnosis3 of invasive breast cancer |
85.9% |
86.1% |
99.8% |
| Lumpectomy |
52.0% |
60.7% |
99.2% |
|
| Mastectomy |
70.8% |
32.6% |
99.8% |
|
| Lumpectomy OR mastectomy |
56.4% |
84.4% |
99.1% |
|
| Lumpectomy AND diagnosis of invasive breast cancer |
89.0% |
59.1% |
99.9% |
|
| Mastectomy AND diagnosis of invasive breast cancer |
85.4% |
31.8% |
99.1% |
|
| (Lumpectomy or mastectomy) AND diagnosis of invasive breast cancer |
87.7% |
82.3% |
99.8% |
|
| (Lumpectomy or mastectomy) OR diagnosis of invasive breast cancer |
56.5% |
88.2% |
99.0% |
|
| Mastectomy OR diagnosis of invasive breast cancer |
79.7% |
87.6% |
99.7% |
|
| Lumpectomy OR diagnosis of invasive breast cancer |
58.2% |
87.6% |
99.1% |
|
| Medicare Benefits Schedule |
Breast radiotherapy |
72.8% |
57.6% |
99.7% |
| Pharmaceutical Benefits Scheme | Dispensed medicine for breast cancer 4 | 45.5% | 65.4% | 98.9% |
1: Comparison to Cancer Registry was restricted to July 2004-December 2005.
2: Reported cancer with birth-year occurring in or overlapping with the period July 2004-December 2005.
3: Primary diagnosis field.
4: Tamoxifen, toremifene, anastrozole, exemestane, letrozole, goserelin, trastuzumab, lapatinib, and medroxyprogesterone 500 mg.